These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 28214033)

  • 1. Reply to Salvador Vale's Letter to the Editor re: Cesare Cozzarini. Whole-pelvis Radiotherapy in the Radiation Treatment of Intermediate- and High-risk Prostate Cancer: How to Improve the Therapeutic Ratio of a Potentially Effective but still Unsatisfactory Treatment? Eur Urol 2017;71:44-5. Preclinical Combinatory Approach to Enhance Radiotherapy Effects and Reduce its Morbidity may be Tested in the Clinic: Wider Whole-pelvis Radiotherapy Fields and Enhanced Antitumoral Effect Mediated by T Lymphocytes: A Legitimate Hypothesis?
    Cozzarini C; Benigni F; Fiorino C; Mondino A; Di Muzio N
    Eur Urol; 2017 Aug; 72(2):e34-e35. PubMed ID: 28214033
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Cesare Cozzarini. Whole-pelvis Radiotherapy in the Radiation Treatment of Intermediate- and High-risk Prostate Cancer: How to Improve the Therapeutic Ratio of a Potentially Effective but still Unsatisfactory Treatment? Eur Urol 2017;71:44-5: Preclinical Combinatorial Approach to Enhance Radiotherapy Effects and Reduce its Morbidity May Be Tested in the Clinic.
    Vale S
    Eur Urol; 2017 Aug; 72(2):e32-e33. PubMed ID: 28214030
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to Berardino De Bari, Filippo Alongi, Stefano Arcangeli's letter to the editor re: Cesare Cozzarini, Claudio Fiorino, Chiara Deantoni, et al. Higher-than-expected severe (grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients. Eur urol 2014;66:1024-30.
    Cozzarini C; Fiorino C; Briganti A; Montorsi F; Di Muzio N
    Eur Urol; 2014 Dec; 66(6):e113-4. PubMed ID: 25199719
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply to Chris Parker, Matthew R. Sydes and Howard Kynaston's letter to the editor re: Firas Abdollah, Nazareno Suardi, Cesare Cozzarini, et al. Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol 2013;63:998-1008.
    Abdollah F; Briganti A
    Eur Urol; 2013 Nov; 64(5):e103-4. PubMed ID: 23915876
    [No Abstract]   [Full Text] [Related]  

  • 5. Whole-pelvis Radiotherapy in the Radiation Treatment of Intermediate- and High-risk Prostate Cancer: How to Improve the Therapeutic Ratio of a Potentially Effective but still Unsatisfactory Treatment?
    Cozzarini C
    Eur Urol; 2017 Jan; 71(1):44-45. PubMed ID: 27600590
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Cesare Cozzarini, Claudio Fiorino, Chiara Deantoni, et al. Higher-than-expected severe (grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients. Eur urol 2014;66:1024-30.
    De Bari B; Alongi F; Arcangeli S
    Eur Urol; 2014 Dec; 66(6):e111-2. PubMed ID: 25190611
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to Filippo Alongi, Rosario Mazzola, Dario Aiello and Matteo Salgarello's Letter to the Editor re: Re: Daniel E. Spratt, Hebert A. Vargas, Zachary S. Zumsteg, et al. Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage. Eur Urol 2017;71:37-43. A Step Forward in the Era of Functional Imaging?: Functional Imaging and Micrometastatic Disease: Implications for Radiotherapy Field Design.
    Spratt DE; Zelefsky MJ
    Eur Urol; 2017 Apr; 71(4):e123-e124. PubMed ID: 27836418
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to Kwang Hyun Kim and Koon Ho Rha's letter to the editor Re: Steven Joniau, Laura Van den Bergh, Evelyne Lerut, et al. Mapping of pelvic lymph node metastases in prostate cancer. Eur Urol 2013;63:450-8.
    Tosco L; Van den Bergh L; Joniau S
    Eur Urol; 2013 Sep; 64(3):e57-8. PubMed ID: 23769590
    [No Abstract]   [Full Text] [Related]  

  • 9. Reply to Henk G. van der Poel, Tessa Buckle and Renato Valdes Olmos' letter to the editor re: Steven Joniau, Laura Van den Bergh, Evelyne Lerut, et al. Mapping of pelvic lymph node metastases in prostate cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.06.057.
    Joniau S; Van den Bergh L
    Eur Urol; 2013 Feb; 63(2):e21-2. PubMed ID: 23149147
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Daniel E. Spratt, Herbert A. Vargas, Zachary S. Zumsteg, et al. Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage. Eur Urol 2017;71;37-43: High-dose Radiotherapy and Pelvic Lymph Nodal Irradiation for High-risk Prostate Cancer in the Image-guided Radiotherapy Era.
    Fodor A; Fiorino C; Picchio M; Di Muzio N
    Eur Urol; 2017 Jun; 71(6):e179-e180. PubMed ID: 28065538
    [No Abstract]   [Full Text] [Related]  

  • 11. Is IMRT needed to spare the rectum when pelvic lymph nodes are part of the initial treatment volume for prostate cancer?
    Sanguineti G; Cavey ML; Endres EJ; Brandon GG; Bayouth JE
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):151-60. PubMed ID: 16198066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosimetric study of pelvic proton radiotherapy for high-risk prostate cancer.
    Chera BS; Vargas C; Morris CG; Louis D; Flampouri S; Yeung D; Duvvuri S; Li Z; Mendenhall NP
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):994-1002. PubMed ID: 19619961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re: Kenneth A. Iczkowski's Letter to the Editor re: Re: Rodolfo Montironi, Silvia Gasparrini, Roberta Mazzucchelli, et al's Letter to the Editor re: Karim A. Touijer, James A. Eastham. The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer. Eur Urol 2016;70:738-9: Sentinel Lymph Nodes in Adipose Tissue Surrounding the Prostate Gland and Seminal Vesicles as Observed in Virtual Whole-mount Histologic Slides. Eur Urol 2017;71:e73-5.
    Montironi R; Lopez-Beltran A; Cheng L; Gasparrini S; Montironi MA; Massari F; Scarpelli M; Montorsi F
    Eur Urol; 2017 Aug; 72(2):e37-e38. PubMed ID: 28292549
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply to Mustafa Z. Temiz and Huseyin Besiroglu's Letter to the Editor re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. Eur Urol 2017;72:910-7.
    Gandaglia G; Fossati N; Montorsi F; Briganti A
    Eur Urol; 2018 May; 73(5):e131-e132. PubMed ID: 29395499
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical outcomes of whole pelvis radiotherapy and stereotactic body radiotherapy boost for intermediate- and high-risk prostate cancer.
    Kim HJ; Phak JH; Kim WC
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e342-e347. PubMed ID: 26846353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reply from Authors re: Ronald C. Chen. Decisions Regarding Whether to Use Androgen Deprivation Therapy with Radiotherapy in Prostate Cancer: Is Cardiovascular Mortality the Most Relevant Outcome? Eur Urol 2016;69:211-2: Outcomes for Favorable and Unfavorable Intermediate Risk Prostate Cancer Patients Receiving Radiation Therapy With or Without Short-term Androgen Deprivation Therapy.
    Voog JC; Paulus R; Efstathiou JA
    Eur Urol; 2016 Feb; 69(2):212-3. PubMed ID: 26443430
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply to Alan Dal Pra, Stephane Supiot and Pirus Ghadjar's Letter to the Editor re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. Eur Urol 2017;72:910-7.
    Gandaglia G; Fossati N; Montorsi F; Briganti A
    Eur Urol; 2018 Feb; 73(2):e36-e37. PubMed ID: 28890246
    [No Abstract]   [Full Text] [Related]  

  • 18. Re:Mark K. Buyyounouski. Radiobiological modeling and the study of hypofractionated radiotherapy for prostate cancer. Eur Urol 2014;66:1031-2.
    Fiorino C; Briganti A; Cozzarini C
    Eur Urol; 2015 Mar; 67(3):e56-7. PubMed ID: 25466947
    [No Abstract]   [Full Text] [Related]  

  • 19. Defining the "Hostile Pelvis" for Intensity Modulated Radiation Therapy: The Impact of Anatomic Variations in Pelvic Dimensions on Dose Delivered to Target Volumes and Organs at Risk in Patients With High-Risk Prostate Cancer Treated With Whole Pelvic Radiation Therapy.
    Yirmibeşoğlu Erkal E; Karabey S; Karabey A; Hayran M; Erkal HŞ
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):894-903. PubMed ID: 26104941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reply to Pirus Ghadjar and Thomas Wiegel's Letter to the Editor re: Daniel E. Spratt, Robert T. Dess, Zachary S. Zumsteg, et al. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. Eur Urol 2018;73:156-65: Salvage Radiotherapy and Hormone Therapy: Change Is Coming, Just Not Quite Yet.
    Spratt DE; Dess RT; Feng FY
    Eur Urol; 2018 Mar; 73(3):e64-e65. PubMed ID: 29111144
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.